NCT07144462View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

January 14, 2027

Study Completion Date

January 14, 2027

Conditions
Autoimmune
Interventions
DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide (C)

Specified dose on specified days

GENETIC

NEUK203-215 Injection

Specified dose on specified days

Trial Locations (1)

200131

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Neukio Biotherapeutics (Shanghai) Co., Ltd.

INDUSTRY